What is included in after treatment monitoring of breast masses?

Updated: Jul 27, 2020
  • Author: Andrew C Miller, MD; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD  more...
  • Print

For breast cancer screening guidelines, see the Guidelines section.

Future studies are needed to determine the efficacy and effectiveness of breast cancer screening with mammography in women aged 40-49 years. Some research shows a modest decrease in breast cancer mortality when women in this age group are screened; however, further research is needed to compare risks of overdiagnosis (one study suggests 1 in 424 women screened would be overdiagnosed) versus potential benefits of screening. [30, 77]

Similar rates of cancer detection have been found between short-term interval follow-up (SIFU) and return to annual screening (RTAS) after benign breast biopsy with no significant differences in stage, tumor size, or nodal status, although the present study was limited by sample size. [78] Additionally, positive predictive values have been reported not to change in patients receiving 6 and 12-month re-biopsy follow-up. [79] These findings suggest that patients with benign radiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!